Eikonoklastes Therapeutics, a Cincinnati, Ohio-based preclinical stage biopharmaceutical company, raised an undisclosed amount in Series A funding.
The round was led by CincyTech with participation from New York-based Elk Capital Ventures, Jobs Ohio, Rev1, and other undisclosed investors
The company intends to use the funds to conduct Investigational New Drug (IND) enabling studies for Eikonoklastes Therapeutics’ L-ICON3 immune conjugate platform.
Led by Chief Executive Officer, Bruce Halpryn, Ph.D., and Sam Lee, MD/MBA co-founder and Chief Business Officer, Eikonoklastes is a preclinical stage biopharmaceutical company developing next-generation tissue factor (TF) immunotherapies to treat a broad range of cancers beginning with Triple Negative Breast Cancer (TNBC), a lethal form of breast cancer that comprises 15% of all breast cancers. The therapies also have the potential to address several other non-cancer diseases with significant unmet clinical need. The company has engineered molecules which attack three key components of the tumor microenvironment (the tumor cells, the diseased neovasculature, and tumor stem cells) by activating the body’s natural immune system and is therefore efficacious without harming normal cells.